Immutep (IMMP) Retained Earnings (2011 - 2025)
Immutep's (IMMP) quarterly Retained Earnings came in at $24.7 million in Q4 2025, up 9.62% YoY from $22.5 million in Q4 2024, and down 10.33% on a QoQ basis from $27.5 million in Q2 2025.
Immutep (IMMP) Retained Earnings (2011 - 2025) Analysis & Trends
Immutep (IMMP) has 15 years of Retained Earnings data on file, last reported at $24.7 million in Q4 2025.
- Quarterly Retained Earnings rose 9.62% year-over-year to $24.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $24.7 million (up 9.62% YoY) and the FY2025 annual result came in at $27.5 million, up 110.92% from the prior year.
- Retained Earnings eased to $24.7 million in Q4 2025, from $27.5 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $27.5 million in Q2 2025 to a low of -$252.2 million in Q2 2024.
- A 5-year average of -$4.8 million and a median of $21.6 million in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2021 — Retained Earnings surged 114.7% — and 2024, when it sank 1352.34%.
- Tracing IMMP's Retained Earnings over 5 years: stood at $25.1 million in 2021, then fell by 29.27% to $17.7 million in 2022, then grew by 10.37% to $19.6 million in 2023, then gained by 14.97% to $22.5 million in 2024, then rose by 9.62% to $24.7 million in 2025.
- The last three Retained Earnings figures came in at $24.7 million (Q4 2025), $27.5 million (Q2 2025), and $22.5 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | Immutep | 57.14 Mn | -7.95 Mn | - | -319.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 24.69 Mn |
| Jun 30, 2025 | 27.53 Mn |
| Dec 31, 2024 | 22.52 Mn |
| Jun 30, 2024 | -252.17 Mn |
| Dec 31, 2023 | 19.59 Mn |
| Jun 30, 2023 | 20.14 Mn |
| Dec 31, 2022 | 17.75 Mn |
| Jun 30, 2022 | 20.78 Mn |
| Dec 31, 2021 | 25.09 Mn |
| Jun 30, 2021 | 26.56 Mn |
| Dec 31, 2020 | 47.43 Mn |
| Jun 30, 2020 | -180.70 Mn |
| Dec 31, 2019 | 44.55 Mn |
| Jun 30, 2019 | 45.90 Mn |
| Dec 31, 2018 | 47.38 Mn |
| Jun 30, 2018 | 49.11 Mn |
| Jun 30, 2017 | -174.16 Mn |
| Mar 31, 2017 | 46.87 Mn |
| Jun 30, 2016 | 47.24 Mn |
| Jun 30, 2015 | 4.10 Mn |